linjc16/ctgov huggingface dataset:
EarlySense Monitoring Device Evaluation on CHF Patients

Study Overview
=================
Brief Summary
-----------------
CHF patients will be monitored using EarlySense ES-16 device and will simultaneously fill diaries and log their weight daily. The data collected and analyzed by the ES-16 device will be correlated with the CHF status data.

Official Title
-----------------
EarlySense Monitoring Device Evaluation on CHF Patients

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Device: EarlySense monitoring device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 45 years old CHF class II or III with LVEF<40% Hospitalized at least once for CHF deterioration over previous 12 month period Able and willing to cooperate with this trial for at least a 3 month period Home close to participating center Exclusion Criteria: Recent (within 3 month) admission to ICU or CC-ICU due to severe CHF episode requiring artificial ventilation Asthma or COPD

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EarlySense monitoring device|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CHF |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congestive, Heart, Failure, CHF
Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function

Study Overview
=================
Brief Summary
-----------------
To determine whether in the laser Doppler flowmetric parameters characteristic of endothelial dysfunction at patients with clinically manifest atherosclerosis any change can be detected at plavix (clopidogrel) treatment. Laser Doppler /LD/ measurement combined with iontophoresis evaluates the effect of acetylcholine /ACh/ /endothelium dependent/ and sodium nitroprusside /NSP/ /endothelium independent/ on the microcirculation of the skin

Official Title
-----------------
Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Drug: Clopidogrel (Plavix)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Proven, peripheral arterial disease, Fontain II-III stage, patient submitted to secondary prophylactic thrombocyte aggregation inhibiting treatment Doppler index < 0,8 Exclusion Criteria: Hypersensitivity to the active ingredient or one of the components of the drug Active pathological bleeding, e.g. gastric ulcer, intracranial bleeding Pregnancy, breast-feeding Severe, known hepatic insufficiency Severe, known renal insufficiency The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Clopidogrel (Plavix)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of the laser Doppler parameters measured after three months clopidogrel /75 mg/day/ treatment compared to the pre-treatment values. |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of clopidogrel /75 mg/day/ treatment |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fontain II-III stage
Abdominal Pain and Symptoms Post Gastric Sleeve

Study Overview
=================
Brief Summary
-----------------
Exploration of abdominal pain post sleeve gastrectomy in morbid obese patients

Detailed Description
-----------------
The primary aim is to evaluate abdominal pain in morbid obese patients before and after sleeve gastrectomy. The investigators will especially focus on chronic abdominal pain, and its relation to quality of life and weight loss. In a sub-analysis the investigators will compare the findings of the present cohort with patients operated with Roux-en-Y gastric bypass. Primary endpoints/outcomes: - Define the prevalence of chronic abdominal pain 2 years after sleeve gastrectomy Secondary endpoints/outcomes: - Evaluate and characterise chronic abdominal pain in regard to: Weight development Obesity-related comorbidities Health-related quality of life Postoperative complications Metabolic effects after surgery Nutritional status Socioeconomic status

Official Title
-----------------
Chronic Abdominal Pain and Discomfort in Morbid Obese Patients Before and After Sleeve Gastrectomy

Conditions
-----------------
Abdominal Pain, Quality of Life

Intervention / Treatment
-----------------
* Other: Questinnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients undergoing sleeve gastrectomy at the Center for Morbid Obesity and Bariatric Surgery, Oslo University Hospital and a collaborating center. Signed written and informed consent for study enrollment Exclusion criteria Patients who dont understand Norwegian language Previous bariatric surgery Indication for sleeve gastrectomy for other reasons than for morbid obesity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questinnaire|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic abdominal pain 2 years after gastric sleeve | questionnaire | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life related to abdominal pain and symptoms | questionnaire (SF-36v2, OP scale) | 2 years |
Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer

Study Overview
=================
Brief Summary
-----------------
The investigator propose to evaluate the interest of the provision of a suitable treadmill offering fall protection and verticalization assistance.

Official Title
-----------------
Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer

Conditions
-----------------
Oncology, Adapted Physical Activity

Intervention / Treatment
-----------------
* Other: Adapted walking platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with cancer Patient over 70 years old hospitalized 48 hours or more Patient identified as eligible for medical prescription of Adapted physical activity Mastery of the French language ; Patient affiliated to a social security scheme Patient giving written consent Exclusion Criteria: Patient totally unable to communicate Patient in terminal palliative care Patient with a size <1m35 or> 2m and / or a weight> 130kg Patient unable to perform Adapted physical activity sessions Patient unable to wear a restraint harness. Patient deprived of liberty or under guardianship Patient unable to comply with protocol requirements for geographical, social or psychopathological reasons

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Adapted walking platform<br> | Other: Adapted walking platform<br>* The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient adherence to use a walking Platform | Adapted physical activity on a walking platform will be considered feasible if > or = to 70% of patients perform > or = to 2 sessions of 6 minutes or more during hospitalization for cancer lasting > or = to 48h | 2 days |
Construction of the Patient-CenteredMolecular Pathology Diagnostic Center

Study Overview
=================
Brief Summary
-----------------
The investigators want to achieve the goal of diagnosis in early phase, accurate treatment and existence for a long period in order to screen in early phase, diagnose in clinical trial, choose treatment and evaluate prognosis of cancers by establishing molecular pathology tools.

Detailed Description
-----------------
This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cervical cancer, cancer of the womb, ovarian cancer, carcinoma of urinary bladder, kidney cancer and so on. The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis

Official Title
-----------------
Construction of the Patient-CenteredMolecular Pathology Diagnostic Center

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 20 years old all kinds of cancer patients Exclusion Criteria: under 20 years old none cancer patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer
Role of B2 Adrenergic Receptors in Labor Pain

Study Overview
=================
Brief Summary
-----------------
The study aims to understand why labor is more painful for some women compared to others. The study will study whether a woman's baseline pain sensitivity, beta2 adrenergic receptor genotype is related to her pain in labor for the birth of a first child.

Detailed Description
-----------------
Other than parity, and infant size, the etiology of the great variability in labor pain us unknown. Previous studies have demonstrated that baseline pain sensitivity is related to postoperative pain and narcotic requirement. We hypothesize that baseline pain sensitivity is related to pain in labor. The study will determine baseline sensitivity to heat, cold and pressure as measurement of pain sensitivity. Furthermore, b2 adrenergic genotype has recently been identified as a potential determinant of pain sensitivity. The investigators will determine whether B2 receptor haplotype is an independent predictor of pain experienced in labor.

Official Title
-----------------
Role of B2 Adrenergic Receptors in Labor Pain

Conditions
-----------------
Pain, Pain Threshold, Labour Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: nulliparous women Third trimester of pregnancy on enrollment Exclusion Criteria: Chronic Pain Pain medication utilization Large for gestational age baby Small for gestational age baby Systemic illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetic, pain, obstetrical
Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the adherence to the antiemesis NCCN guideline in Chinese patients of gynecologic malignancies, who are given chemotherapy treatment. The risk of chemotherapy induced nausea and vomiting (CINV) is calculated by the questionnaire supported by the website CINV Risk Assessment (http://www.riskcinv.org/).

Official Title
-----------------
Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline in Chinese Patients of Gynecologic Malignancies

Conditions
-----------------
Gynecologic Cancer, Chemotherapy-induced Nausea and Vomiting

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good performance status Aged 18 years or older Signed an approved informed consents Exclusion Criteria: Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk of chemotherapy induced nausea and vomiting | The risk of chemotherapy induced nausea and vomiting is calculated by the questionnaire supported by the website CINV Risk Assessment (http://www.riskcinv.org/). The difference of patients adhered to and not to NCCN guideline is compared. | One year |
Stress-Reducing Interventions in HIV+ Patients: Pilot

Study Overview
=================
Brief Summary
-----------------
The primary aim of this project is to examine the efficacy of prolonged exposure (PE) therapy at reducing HIV-related PTSD symptoms, increasing adherence to antiretroviral medication regimens, and increasing health-related quality of life (QOL) in HIV+ patients.

Detailed Description
-----------------
HIV+ patients will be randomized to receive either PE therapy (up to 18 possible sessions) or weekly symptom monitoring (described below) and will complete measures of PTSD, adherence, and QOL pre- and post-intervention and at 3- and 6-month follow-up assessments. Secondary analyses will examine the impact of the intervention on disorders commonly comorbid with PTSD (i.e., anxiety, mood, and substance abuse/dependence disorders).

Official Title
-----------------
Pilot Intervention for PTSD, Nonadherence, and HIV Risk

Conditions
-----------------
Stress Disorders, Post-Traumatic, HIV Infections

Intervention / Treatment
-----------------
* Behavioral: Prolonged Exposure Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be HIV+ Must meet PTSD diagnostic criteria Must be taking HIV medications Must be able to read and write in English Exclusion Criteria: Current or previous diagnosis of schizophrenia, any current diagnosis with psychotic features, or current suicidal ideation Being in a current abusive relationship or ongoing intimate relationship with one's assailant Mental retardation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Prolonged Exposure Therapy. | Behavioral: Prolonged Exposure Therapy<br>* Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.<br>|
| No Intervention: 2<br>Weekly monitoring/Waitlist Control Group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PTSD symptoms |  | pre- & post-intervention, 3-month post, & 6-month post | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to HIV medications |  | pre- & post-intervention, 3-month post, & 6-month post | 
| Health-related Quality of Life |  | pre- & post-intervention, 3-month post, & 6-month post | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prolonged Exposure Therapy, Adherence to HIV Medications, Complementary Therapies
Natural History of Urticaria Pigmentosa in Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how long the skin lesions usually last and what kind of symptoms and signs children with urticaria pigmentosa may develop over the years. This information will allow physicians to better care for patients who have been diagnosed with this disease and to provide their parents with more complete information regarding what to expect for the future of their child. This research is being done because many unanswered questions remain regarding children with urticaria pigmentosa and its course.

Detailed Description
-----------------
This study involves children, of age 0-18 years old who are diagnosed with urticaria pigmentosa during their visit at the Pediatric Dermatology Clinic. Parents and child will be interviewed to gain medical and family history, in addition, the doctor will perform a physical exam and take a photograph. Children older than 4 years of age will complete the Children Dermatology Life Quality Index. Children less than 4 years of age with an active disease will have laboratory tests requiring a sample of blood (1 teaspoon). Patients will receive $50 for their first office visit as financial reimbursement for participating in the study.

Official Title
-----------------
Natural History of Urticaria Pigmentosa in Children

Conditions
-----------------
Urticaria Pigmentosa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 0-18 years old at diagnosis of UP 3 or more mastocytomas (diagnosis can be based on clinical exam; biopsy only necessary if diagnosis is in question) patients recruited from Children's Hospital of Wisconsin Dermatology Clinic Exclusion Criteria: Less than 3 mastocytomas Diffuse mastocytosis TMEP residence is out of Wisconsin/Illinois area or the United States

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urticaria pigmentosa, mastocytosis, mastocytomas
3D Personalized Modelization of the Hand Using EOS Imaging System

Study Overview
=================
Brief Summary
-----------------
This study aims to compare the quality of 3D hand modelization with EOS imaging with gold-standard computed tomography

Official Title
-----------------
3D Personalized Modelization of the Hand Using EOS Imaging System

Conditions
-----------------
Hand Injuries

Intervention / Treatment
-----------------
* Device: EOS hand imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with hand/wrist CT required Informed consent form signed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EOS imaging<br>For each patient, EOS images are compared with computed tomography [CT] images | Device: EOS hand imaging<br>* For each patient, EOS images are compared with CT images<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Data obtained through EOS imaging | Precision and correlation of the 3D modelization of hand is compared between the two imaging methods | Day 60 | 
| Data obtained through standard CT | Precision and correlation of the 3D modelization of hand is compared between the two imaging methods | Day 60 |